Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient

Patent metadata

Field	Value
Publication number	US-9296751-B1
Application number	US-201514884179-A
Country	US
Kind code	B1
Filing date	Oct 15, 2015
Priority date	Oct 16, 2014
Publication date	Mar 29, 2016
Grant date	Mar 29, 2016

Abstract

Provided are an indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof, and a method for preparing the same. The indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof may function as an agonist of cystic fibrosis conductance transmembrane regulator, and thus may be useful for an agent for preventing or treating diseases caused by degradation of activity of cystic fibrosis conductance transmembrane regulator and for a pharmaceutical composition for stimulating proliferation of stem cells.

First claim

What is claimed is:

1. An indolizino[3,2-c]quinoline derivative represented by the following Chemical Formula 1 or pharmaceutically acceptable salt thereof:

In Chemical Formula 1,
R 1 , R 2 , R 3 , R 4 and R 5 are the same or different, and each independently represents H, F, Cl, Br, I, a C1-C6 alkyl, C1-C6 alkoxy, COOR 7 , aryl and a heteroaryl;
R 6 is s…

Assignees

• Univ Yonsei Iacf

Inventors

• Kim Ikyon
• Namkung Wan
• Sung Jonghyuk

Classifications

• A61K31/277

  Human Necessities · mapped topic

• C07D471/14 Primary

  Chemistry & Metallurgy · mapped topic

• C07D459/00 Primary

  Chemistry & Metallurgy · mapped topic

• A61K31/437

  Human Necessities · mapped topic

• C07D471/12

  Chemistry & Metallurgy · mapped topic